More Than Half of What Britain Eats Is Ultra-Processed. Here Is What the Science Can Now Say About It.

Ultra-processed food has gone from a term used mainly by nutrition researchers to a fixture of everyday conversation in a remarkably short time. The science has been moving almost as quickly. A major series in The Lancet last November pulled together the global evidence and called for governments to act. A UCL trial put the question to a direct test, feeding people two diets that matched on nutrients but differed in processing. And this January, the UK’s long-delayed restrictions on junk food advertising finally took legal effect, built on a definition that, as Cambridge researchers have shown, only partly overlaps with what counts as ultra-processed. Together they show both how much stronger the evidence has become and how much it still struggles to fit the way policy is written.

A Diet Built Mostly From Factory Formulations

Ultra-processed foods are defined under the Nova classification, devised in 2009 by Carlos Monteiro of the University of São Paulo, as industrial formulations typically containing ingredients rarely used in home cooking, such as emulsifiers, flavourings and preservatives. In the UK they make up the bulk of what people eat. An analysis of the National Diet and Nutrition Survey for 2008 to 2014 found that ultra-processed foods supplied 56.8 per cent of total energy intake, while unprocessed or minimally processed foods supplied just 30.1 per cent. As the share of ultra-processed food in someone’s diet rose, so did their intake of free sugars, saturated fat and salt, while protein, fibre and potassium fell.

The Lancet’s three-paper series, published online on 18 November 2025 with Monteiro among its lead authors, set out to test whether this dietary pattern is driving the rise in chronic disease. Its authors reviewed the epidemiological evidence linking higher consumption of ultra-processed food with obesity, type 2 diabetes, cardiovascular disease and early death, and according to a published summary of the series, 92 of the 104 long-term studies it examined found an increased risk of chronic disease. Much of that evidence comes from observational studies, which show association rather than proof of cause, but the authors argued that waiting for perfect evidence risks delaying measures already known to improve diets.

Same Nutrients, Different Processing

The UCL trial, published in Nature Medicine in August 2025 and led by Dr Samuel Dicken, was designed to get past the limits of observational research. It enrolled 55 adults and gave each of them two eight-week diets in turn, separated by a four-week break. Both diets were matched to the Eatwell Guide, the government’s official advice on a balanced diet, for fat, saturated fat, protein, carbohydrate, salt, fibre, fruit and vegetables. The only planned difference was processing: overnight oats and homemade spaghetti Bolognese on one diet, breakfast oat bars and a lasagne ready meal on the other. Participants were sent more food than they needed and told to eat as much or as little as they liked.

Both diets led to weight loss, but the minimally processed one produced nearly twice as much, a 2.06 per cent reduction against 1.05 per cent, equivalent to an estimated daily calorie deficit of 290 kilocalories compared with 120. The extra loss came from fat and body water rather than muscle, and participants reported markedly better control over their cravings on the minimally processed diet. “Previous research has linked ultra-processed foods with poor health outcomes. But not all ultra-processed foods are inherently unhealthy based on their nutritional profile,” Dicken said, explaining that the trial was designed to separate processing from nutrition.

The results were not one-sided. Secondary markers such as blood pressure, cholesterol and blood glucose showed no significant harm from the nutritionally balanced ultra-processed diet, and mostly no meaningful difference between the two. The researchers cautioned that longer studies would be needed to judge those measures properly, and the eight-week periods are short compared with the years over which diet shapes health.

A Policy Aimed at a Different Target

On 5 January 2026, new restrictions on advertising “less healthy” food and drink took legal effect in the UK, after a voluntary period that began the previous October. Adverts for identifiable less healthy products can no longer appear on television or on-demand services between 5.30am and 9pm, and paid-for online advertising of them is banned outright. Brand advertising that does not show an identifiable product is exempt. The government estimates the restrictions will prevent around 20,000 cases of childhood obesity.

The rules are built on the UK’s nutrient profiling model, which identifies foods high in fat, salt or sugar, rather than on how heavily a food is processed. Researchers at the MRC Epidemiology Unit in Cambridge examined how far the two definitions overlap, using eleven years of National Diet and Nutrition Survey data published in BMJ Nutrition, Prevention and Health in 2025. They found that 59.8 per cent of energy in the UK diet came from ultra-processed foods and 47.4 per cent from foods high in fat, salt or sugar, but that only 58.7 per cent of the energy from ultra-processed foods also counted as high in fat, salt or sugar. The UK’s profiling model, they concluded, captures at best just over half of the ultra-processed food people eat. The biggest groups of ultra-processed foods that escape it are low-calorie soft drinks and white bread.

Where Processing Fits

The exact share of ultra-processed food in the British diet varies a little depending on the survey years and method used, but every estimate puts it above half. Set side by side, the three strands describe a field moving from association towards mechanism, and a policy system still catching up. The Lancet series makes the population-level case that ultra-processed diets are displacing healthier ones and tracking with chronic disease. The UCL trial suggests that processing may matter for weight even when nutrients are held constant, while also showing that a carefully balanced ultra-processed diet is not automatically harmful over a couple of months. And the advertising rules, the most significant food policy to take effect in years, target fat, salt and sugar rather than processing, leaving close to half of ultra-processed energy outside their reach. Whether future policy should regulate processing directly is now one of the central questions in UK nutrition science, and it is one the evidence is only just beginning to be strong enough to answer.

Sources: The Lancet (Ultra-Processed Foods and Human Health series, 2025); Nature Medicine (Dicken et al, 2025); UCL; Nutrients (Rauber et al, 2018); BMJ Nutrition, Prevention and Health (MRC Epidemiology Unit, 2025); Committees of Advertising Practice; Association for the Study of Obesity.

Author

Leave A Comment

Graham Combe

Strategic Consultant,
Life Sciences Week
+44 (0) 121 227 4156
[email protected]

Bio

Graham Combe is an experienced strategic consultant, relationship builder, and entrepreneur in the global life sciences sector. He holds a BSc (Hons) in Chemistry from University College London (UCL) and spent over a decade with Nature, where he pioneered key initiatives such as Nature’s BioPharma Dealmakers and Nature’s SciCafe.

In May 2011, he founded Biosell UK, a consulting and event management firm that collaborates with global life science publishers, event organizations, and marketing partners. Beyond BioSell, Combe is the founder or co-founder of several prominent networking and thought-leadership platforms, including #BiotechBuddies, #coffeebuddies, the #AgileLeaders Forum, and the Creative Disruption Forum—the latter three events co-hosted with his business partner, Professor Tony Sedgwick.

Specializing in the early-to-mid stages of drug development (from pre-clinical research through Phase 3 and clinical proof-of-concept), Graham focuses on facilitating forums to promote peer-to-peer discussion, strategic growth, investment and meaningful connections between biotech innovators, investors, and industry service providers.

Apply for a complimentary Conference Day VIP Pass

Apply for a complimentary Conference Day VIP Pass

Complimentary Conference Day VIP Passes are reserved for senior leaders and decision-makers with influence over purchasing, commissioning, investment or technology advancements and adoption across UK life sciences.

A Conference Day VIP Pass includes:

  • Complimentary access-all-areas to the Launch Day Conference
  • Access to the dedicated VIP green room alongside Conference speakers
  • Access to all general keynote, panel and programme sessions
  • Curated networking opportunities
  • Opportunities to meet conference speakers and other approved VIP attendees

The VIP Pass applies to the Launch Day Conference only. It does not include admission to the Life Sciences Week Gala Dinner or other separately ticketed events.

Applications are reviewed individually and submitting this form does not guarantee a complimentary pass. To maintain a balanced, high-quality audience, we may limit the number of VIP Passes issued to any one organisation.

    First Name *

    Last Name *

    Work Email Address *

    Telephone Number *

    Job Title *

    Organisation *

    LinkedIn

    Organisation Information

    Which best describes your organisation? *


    If other, please specify

    Which best describes your level of seniority? *

    If other, please specify

    Which areas are you responsible for or directly involved in? *

    If other, please specify

    What best describes your role in purchasing, investment, commissioning or adoption decisions? *

    Attendance Information

    Briefly, what is the number one thing you are hoping to get out of attending Life Sciences Week 2026? *

    Final Confirmation

    Is your role primarily focused on selling products or services, consultancy, account management or business development? *

    Please Confirm *

    I understand that VIP applications are subject to review and approval.
    I understand that the complimentary VIP Pass covers the Life Sciences Week Launch Day Conference only and does not include the Gala Dinner Awards or other separately ticketed events.
    The information supplied in this application is accurate.

    Shabna Raja

    Advisory Partner,
    Life Sciences Week
    +44 (0) 121 227 4156
    [email protected]

    Bio

    Shabna Raja is a senior leader in enterprise transformation within Life Sciences, with over 20 years’ experience spanning pharma, consumer health and large-scale digital programmes.

    She specialises in bridging strategy and execution – helping organisations translate AI, data and digital innovation into tangible business outcomes. Her work focuses on complex transformation
    initiatives across commercial, data and operating model domains within regulated environments.

    Shabna spent seven years at GSK, where she played a key role in transformation programmes, including as part of the Consumer Health joint venture with Pfizer — one of the most significant integrations in the sector. This experience provided her with deep expertise in  organisational change, integration and operating model evolution at global scale.

    More recently, she has spent over three years working closely with Haleon through a strategic
    services partnership, leading enterprise client engagement and managing a multi-million-pound account while supporting transformation across a newly independent global organisation.

    Her experience spans the end-to-end life sciences value chain, including R&D, commercial, supply chain and patient engagement, giving her a holistic perspective on how technology and transformation can unlock value across the industry.

    Amjad Khan

    Executive Partner,
    Life Sciences Week
    +44 (0) 121 227 4156
    [email protected]

    Bio

    Amjad Khan is a UK-based entrepreneur, AI strategist, and senior technology leader with over 15 years of experience at Pfizer, where he held multiple leadership roles across digital strategy and transformation. As Global Digital Client Partner, he was responsible for digital strategy and execution across Global Business Units covering Vaccines, Hospital, and Medical Affairs. Most notably, he led the commercial launch for the Covid franchise transforming and accelerating the model for how new medicines are brought to market.

    Following his tenure at Pfizer, Amjad channelled his expertise into building at the frontier of AI. His work spans AI leadership, stakeholder engagement, and agile delivery helping organisations adopt and scale emerging  technologies to drive meaningful outcomes.

    Dr. Richard Fallon | Business Consultant | WM Life Sciences

    Dr. Richard Fallon

    Co Founder, Life Sciences Week 
    +44 (0) 121 227 4156
    [email protected]

    Bio

    Dr Richard Fallon is an entrepreneur and ecosystem builder who connects industry leaders, investors and public-sector stakeholders to accelerate collaboration and commercial growth.

    As the Founder of the Technology Supply Chain and co-founder of the Innovation Awards, he has spent more than two decades convening influential networks that help emerging businesses find capital, strategic partners and new routes to market.

    Richard’s work spans leadership and consultancy across major organisations, alongside building membership and partnership platforms that bring universities, industry and investors into the same room – and turn conversations into practical outcomes.

    With his focus on life sciences, Richard supports organisations and people driving breakthroughs in healthcare, biotechnology, medical technology and advanced research. He is passionate about creating the conditions for transformative ideas to move from concept to real-world impact – by connecting innovators with the funding, expertise and opportunities they need to scale.

    Through Life Sciences Week, Richard is championing the UK’s world-class life sciences community and helping position it at the forefront of innovation, investment and patient outcomes.

    Amy Deakin | Chief of Staff | WM Life Sciences

    Amy Deakin

    Event Managing Director,
    Life Sciences Week
    +44 (0) 121 227 4156
    [email protected]

    Bio

    Amy Deakin is a Birmingham-based leader specialising in building partnerships and fostering innovation in the life sciences sector. With a degree in Sport and Exercise Science, Amy brings a grounded understanding of human health and performance to her work and a strong interest in the developments shaping healthcare today.

    Amy is Managing Director of Life Sciences Week, part of the One Thousand Trades Group, and also serves as Director of One Thousand Trades Events. In these roles, she convenes researchers, clinicians and industry leaders to strengthen collaboration, unlock new partnerships and help accelerate real-world innovation across the life sciences ecosystem.

    Her career spans both commercial and third-sector environments. She began in automotive design, delivering projects for Volkswagen, McLaren, Bentley and Jaguar Land Rover, before moving into the third sector with Acorns Children’s Hospice. She later joined Western Union, working as a Partnerships Manager for international payments

    An avid netballer, Amy is a committed advocate for health and wellbeing – bringing energy, clarity and connection to everything she builds, and actively involved as a participant in health related research studies.

      Award Category Voting

      Here's a list of all categories you can vote for. Simply click each category to cast your vote. Voting in each category is not mandatory, so please feel free to click just the category that interests you.

      Day you've not voted in, will be denoted with an ❌

      If you're having issues submitting the form, please ensure all the category boxes are closed and try again.

      Recognising pioneering research, technology, or therapies that are transforming healthcare and biotechnology.

      No VoteProf. Alex RichterBlack Space TechnologyAston Vision Sciences

      Celebrating an emerging leader making significant contributions to the field through research, innovation, or leadership.

      Recognising pioneering research, technology, or therapies that are transforming healthcare and biotechnology.

      No VoteShashank Chaganty – VichagLeah Vanono - PBS InnovationsKloe Avon- KZ Organics

      Honouring successful cross-sector partnerships driving advancements in life sciences, from academia to industry.

      No VoteProf Liam Grover- WMHTIAJudith Stewart- Health Innovation West MidlandsAdam McGuinness - Plug and Play

      Awarding an individual or organisation for exceptional long-term impact on the industry.

      No VoteDavid KidneyMedilink MidlandsUniversity of Birmingham

      Highlighting innovations in treatments, diagnostics, or healthcare delivery that have significantly improved patient outcomes.

      No VoteJean-Louis Duprey - Linear DiagnosticsSian Dunning - MD-TECKarim Vissangy - HoloMedix

      Your Details